Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:40:17 18/07/2024 pm IST 5-day change 1st Jan Change
56.33 USD -0.81% Intraday chart for Cytokinetics, Incorporated -0.07% -32.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating MT
Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing MT
Cytokinetics Insider Sold Shares Worth $1,183,391, According to a Recent SEC Filing MT
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants CI
Cytokinetics Insider Sold Shares Worth $413,106, According to a Recent SEC Filing MT
Transcript : Cytokinetics, Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 11:20 AM
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care Stocks Rise Wednesday Afternoon MT
Sector Update: Health Care MT
Cytokinetics Says Third Party Dropped Takeover Bid Despite Negotiations; Shares Rise MT
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout DJ
Cytokinetics Says Third Party Did Not Move Forward with Acquisition After Talks CI
B. Riley Cuts Price Target on Cytokinetics to $92 From $122, Maintains Buy Rating MT
Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing MT
Truist Securities Lowers Price Target on Cytokinetics to $70 From $86, Maintains Buy Rating MT
Cytokinetics Closes $500 Million Stock Offering MT
JMP Securities Adjusts Cytokinetics Price Target to $78 From $106, Maintains Market Outperform Rating MT
Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC CI
Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating MT
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday MT
Nvidia Earnings Fuel Investor Optimism, Driving Premarket Gains for US Equity Futures MT
Needham Adjusts Price Target on Cytokinetics to $72 From $108, Maintains Buy Rating MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Tech Stocks Rally on NVIDIA Earnings MT
Stocks in motion: e.l.f Beauty soars along with Nvidia Our Logo
Chart Cytokinetics, Incorporated
More charts
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
56.79 USD
Average target price
82.65 USD
Spread / Average Target
+45.53%
Consensus
  1. Stock Market
  2. Equities
  3. CYTK Stock
  4. News Cytokinetics, Incorporated
  5. B. Riley Cuts Price Target on Cytokinetics to $92 From $122, Maintains Buy Rating